Your request to link to rcsb for Poly [ADP-ribose] polymerase 1

---

• 1EFY: crystal structure of the catalytic fragment of poly (adp-ribose) polymerase complexed with a benzimidazole inhibitor (10.1021/JM000950V )
• 1PAX: the catalytic fragment of poly(adp-ribose) polymerase complexed with 3,4-dihydro-5-methyl-isoquinolinone (10.1073/PNAS.93.15.7481 )
• 1UK0: crystal structure of catalytic domain of human poly(adp- ribose) polymerase with a novel inhibitor (10.1016/S0014-5793(03)01362-0 )
• 1UK1: crystal structure of human poly(adp-ribose) polymerase complexed with a potent inhibitor (10.1021/JM0499256 )
• 1WOK: crystal structure of catalytic domain of human poly(adp-ribose) polymerase complexed with a quinoxaline-type inhibitor (10.1016/J.FEBSLET.2005.01.036 )
• 2COK: solution structure of brct domain of poly(adp-ribose) polymerase-1
• 2CR9: solution structure of wgr domain of poly(adp-ribose) polymerase-1
• 2CS2: solution structure of the second zn-finger domain of poly(adp-ribose) polymerase-1
• 2DMJ: solution structure of the first zf-parp domain of human poly(adp-ribose)polymerase-1
• 2JVN: domain c of human parp-1 (10.1021/BI800018A )
• 2L30: human parp-1 zinc finger 1 (10.1016/J.JMB.2011.01.034 )
• 2L31: human parp-1 zinc finger 2 (10.1016/J.JMB.2011.01.034 )
• 2LE0: parp brct domain (10.1186/1472-6807-11-37 )
• 2N8A: 1h, 13c and 15n chemical shift assignments and solution structure for parp-1 f1f2 domains in complex with a dna single-strand break 05-oct-16 2n8a 1 title (10.1016/J.MOLCEL.2015.10.032 )
• 2PAW: the catalytic fragment of poly(adp-ribose) polymerase (10.1021/BI972383S )
• 2PAX: the catalytic fragment of poly(adp-ribose) polymerase complexed with 4-amino-1,8-naphthalimide (10.1021/BI972383S )
• 2RCW: parp complexed with a620223
• 2RD6: parp complexed with a861695
• 2RIQ: crystal structure of the third zinc-binding domain of human parp-1 (10.1074/JBC.M708558200 )
• 3GJW: parp complexed with a968427 (10.1016/J.BMCL.2009.06.016 )
• 3GN7: parp complexed with a861696
• 3L3L: parp complexed with a906894 (10.1016/J.BMCL.2009.12.042 )
• 3L3M: parp complexed with a927929 (10.1021/JM901775Y )
• 3OD8: human parp-1 zinc finger 1 (zn1) bound to dna (10.1074/JBC.M110.202507 )
• 3ODA: human parp-1 zinc finger 1 (zn1) bound to dna (10.1074/JBC.M110.202507 )
• 3ODC: human parp-1 zinc finger 2 (zn2) bound to dna (10.1074/JBC.M110.202507 )
• 3ODE: human parp-1 zinc finger 2 (zn2) bound to dna (10.1074/JBC.M110.202507 )
• 3PAX: the catalytic fragment of poly(adp-ribose) polymerase complexed with 3-methoxybenzamide (10.1021/BI972383S )
• 4AV1: crystal structure of the human parp-1 dna binding domain in complex with dna (10.1038/NSMB.2335 )
• 4DQY: structure of human parp-1 bound to a dna double strand break (10.1126/SCIENCE.1216338 )
• 4GV7: human artd1 (parp1) - catalytic domain in complex with inhibitor me0328 (10.1021/CB4002014 )
• 4HHY: crystal structure of parp catalytic domain in complex with novel inhibitors (10.1021/JM301825T )
• 4HHZ: crystal structure of parp catalytic domain in complex with novel inhibitors (10.1021/JM301825T )
• 4L6S: parp complexed with benzo[1,4]oxazin-3-one inhibitor (10.1016/J.BMCL.2013.06.055 )
• 4OPX: structure of human parp-1 bound to a dna double strand break in complex with (2r)-5-fluoro-2-methyl-2,3-dihydro-1-benzofuran-7- carboxamide (10.1021/JM5002502 )
• 4OQA: structure of human parp-1 bound to a dna double strand break in complex with (2z)-2-(2,4-dihydroxybenzylidene)-3-oxo-2,3-dihydro-1- benzofuran-7-carboxamide (10.1021/JM5002502 )
• 4OQB: structure of human parp-1 bound to a dna double strand break in complex with (2z)-2-{4-[2-(morpholin-4-yl)ethoxy]benzylidene}-3-oxo- 2,3-dihydro-1-benzofuran-7-carboxamide (10.1021/JM5002502 )
• 4PAX: the catalytic fragment of poly(adp-ribose) polymerase complexed with 8-hydroxy-2-methyl-3-hydro-quinazolin-4-one (10.1021/BI972383S )
• 4PJT: structure of parp1 catalytic domain bound to inhibitor bmn 673 (10.1107/S2053230X14015088 )
• 4R5W: human artd1 (parp1) - catalytic domain in complex with inhibitor xav939
• 4R6E: human artd1 (parp1) - catalytic domain in complex with inhibitor niraparib
• 4RV6: human artd1 (parp1) catalytic domain in complex with inhibitor rucaparib (10.1021/ACS.JMEDCHEM.6B00990 )
• 4UND: human artd1 (parp1) - catalytic domain in complex with inhibitor talazoparib (10.1021/ACS.JMEDCHEM.6B00990 )
• 4UXB: human artd1 (parp1) - catalytic domain in complex with inhibitor pj34 (10.1021/ACS.JMEDCHEM.6B00990 )
• 4XHU: the complex structure of timeless_pab and parp-1_catalytic domain (10.1016/J.MOLCEL.2015.07.031 )
• 4ZZZ: structure of human parp1 catalytic domain bound to an isoindolinone inhibitor (10.1021/ACS.JMEDCHEM.5B00680 )
• 5A00: structure of human parp1 catalytic domain bound to an isoindolinone inhibitor (10.1021/ACS.JMEDCHEM.5B00680 )
• 5DS3: crystal structure of constitutively active parp-1 (10.1016/J.MOLCEL.2015.10.013 )
• 5HA9: crystal structure-based design and disovery of a novel parp1 antiagonist (bl-pa10) that induces apoptosis and inhibits metastasis in triple negative breast cancer (10.1038/S41598-016-0007-2 )
• 5KPN: structure of human parp1 catalytic domain bound to a quinazoline-2, 4(1h,3h)-dione inhibitor
• 5KPO: structure of human parp1 catalytic domain bound to a quinazoline-2, 4(1h,3h)-dione inhibitor
• 5KPP: structure of human parp1 catalytic domain bound to a quinazoline-2, 4(1h,3h)-dione inhibitor
• 5KPQ: structure of human parp1 catalytic domain bound to a quinazoline-2, 4(1h,3h)-dione inhibitor
• 5WRQ: structure of human parp1 catalytic domain bound to a quinazoline-2, 4(1h,3h)-dione inhibitor
• 5WRY: structure of human parp1 catalytic domain bound to a quinazoline-2, 4(1h,3h)-dione inhibitor
• 5WRZ: structure of human parp1 catalytic domain bound to a phthalazinone inhibitor
• 5WS0: structure of human parp1 catalytic domain bound to a benzoimidazole inhibitor
• 5WS1: structure of human parp1 catalytic domain bound to a benzoimidazole inhibitor
• 5WTC: structure of human parp1 catalytic domain bound to a quinazoline-2, 4(1h,3h)-dione inhibitor
• 5XSR: novel orally efficacious inhibitors complexed with parp1 (10.1016/J.EJMECH.2018.01.018 )
• 5XST: novel orally efficacious inhibitors complexed with parp1 (10.1016/J.EJMECH.2018.01.018 )
• 5XSU: novel orally efficacious inhibitors complexed with parp1 (10.1016/J.EJMECH.2018.01.018 )
• 6BHV: human parp-1 bound to nad+ analog benzamide adenine dinucleotide (bad) (10.1038/S41467-018-03234-8 )
• 6GHK: human parp1 (artd1) - catalytic domain in complex with inhibitor me0527
• 6I8M: the catalytic fragment of poly(adp-ribose) polymerase complexed with isoindolinone inhibitor (10.1021/ACSMEDCHEMLETT.8B00569 )
• 6I8T: the catalytic fragment of poly(adp-ribose) polymerase complexed with an isoindolinone inhibitor (10.1021/ACSMEDCHEMLETT.8B00569 )
• 6M3I: crystal structure of hpf1/parp1 complex (10.1038/S41467-021-21302-4 )
• 6NRF: crystal structure of human parp-1 art domain bound to inhibitor utt103 (10.1021/ACS.JMEDCHEM.8B01709 )
• 6NRG: crystal structure of human parp-1 art domain bound to inhibitor utt57 (10.1021/ACS.JMEDCHEM.8B01709 )
• 6NRH: crystal structure of human parp-1 art domain bound inhibitor utt63 (10.1021/ACS.JMEDCHEM.8B01709 )
• 6NRI: crystal structure of human parp-1 art domain bound to inhibitor utt83 (10.1021/ACS.JMEDCHEM.8B01709 )
• 6NRJ: crystal structure of human parp-1 art domain bound to inhibitor utt93 (10.1021/ACS.JMEDCHEM.8B01709 )
• 6NTU: crystal structure of human parp-1 art domain bound to inhibitor uktt- 15 (10.1126/SCIENCE.AAX6367 )
• 6VKK: crystal structure of human parp-1 cat domain bound to inhibitor rucaparib (10.1126/SCIENCE.AAX6367 )
• 6VKO: crystal structure of human parp-1 cat domain bound to inhibitor uktt15 (10.1126/SCIENCE.AAX6367 )
• 6VKQ: crystal structure of human parp-1 cat domain bound to inhibitor eb-47 (10.1126/SCIENCE.AAX6367 )
• 6XVW: catalytic domain of human parp-1 in complex with the inhibitor mc2050 (10.1021/ACSMEDCHEMLETT.9B00654 )
• 7AAA: crystal structure of the catalytic domain of human parp1 (apo) (10.1093/NAR/GKAB020 )
• 7AAB: crystal structure of the catalytic domain of human parp1 in complex with inhibitor eb-47 (10.1093/NAR/GKAB020 )
• 7AAC: crystal structure of the catalytic domain of human parp1 in complex with veliparib (10.1093/NAR/GKAB020 )
• 7AAD: crystal structure of the catalytic domain of human parp1 in complex with olaparib (10.1093/NAR/GKAB020 )
• 7CMW: complex structure of parp1 catalytic domain with pamiparib (10.1021/ACS.JMEDCHEM.0C01346 )
• 7KK2: structure of the catalytic domain of parp1 (10.1074/JBC.RA120.016573 )
• 7KK3: structure of the catalytic domain of parp1 in complex with talazoparib (10.1074/JBC.RA120.016573 )
• 7KK4: structure of the catalytic domain of parp1 in complex with olaparib (10.1074/JBC.RA120.016573 )
• 7KK5: structure of the catalytic domain of parp1 in complex with niraparib (10.1074/JBC.RA120.016573 )
• 7KK6: structure of the catalytic domain of parp1 in complex with veliparib (10.1074/JBC.RA120.016573 )
• 7ONR: parp1 catalytic domain in complex with 8-chloroquinazolinone-based inhibitor (compound 9)
• 7ONS: parp1 catalytic domain in complex with isoquinolone-based inhibitor (compound 16)
• 7ONT: parp1 catalytic domain in complex with a selective pyridine carboxamide-based inhibitor (compound 22)
• 7SCY: nuc147 bound to single brct (10.1016/J.MOLCEL.2021.11.014 )